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Denosumab is a more cost-effective treatment alternative in an elderly PMO pop-
ulation. Compared to no treatment, zoledronic acid, and alendronate, denosumab
can improve care in elderly PMO patients above 75 years and at the same time
lower overall treatment costs in Sweden.
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OBJECTIVES: To determine the cost-effectiveness of biologic drugs for moderate to
severe psoriatic arthritis (PsA) using a 40-year German health care perspective.
METHODS: A network meta-analysis of 8 biologics RCTs determined short-term
efficacy using Psoriasis Area and Severity Index 75% (PASI75) and American College
of Rheumatology (ACR) responses and Health Assessment Questionnaire (HAQ)
and PASI improvements. Published evidence and assumptions were used to predict
long-term efficacy using a decision analytic model. Costs included drug acquisi-
tion, administration, monitoring, and hospitalisation. Incremental cost-effective-
ness ratios (ICERs) were calculated using Quality Adjusted Life Years (QALYs), func-
tion (HAQ-adjusted life years), and years in PASI75 response. RESULTS: For the
QALY analysis, golimumab was extended dominated by adalimumab. The incre-
mental costs and QALYs for adalimumab vs. palliative care were €32046 and 0.671,
producing an ICER of €47728/QALY. Etanercept was estimated to provide margin-
ally more QALYs (0.060) at an additional €3461 (ICER of €57380/QALY vs. adali-
mumab). Although infliximab was estimated to give the most QALYs (0.031 more
than etanercept), the cost was an additional €8046 (ICER for infliximab of €260940/
QALY vs. etanercept). Results for the HAQ-adjusted life year analysis were similar,
where adalimumab (€293/HAQ life year) had similar results in comparison to etan-
ercept (€292/HAQ life year). For years in PASI75 response, etanercept became dom-
inated, golimumab gave 2.308 incremental PASI75 life years at an incremental cost
of €29463 (ICER of €12765/PASI75 life year vs. palliative care), adalimumab gave
2.704 incremental PASI75 life years at an incremental cost of €32064 (ICER of €11851/
PASI75 life year vs. palliative care), and infliximab became the optimal strategy
with 4.407 incremental QALYS at an additional €43553 (ICER of €9883/PASI75 life
year vs. palliative care). CONCLUSIONS:Using QALYs, which combine the skin and
joint aspects of disease, adalimumab and etanercept were the most cost-effective
biologic strategies; infliximab gave marginally more benefit at a much higher cost.
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OBJECTIVES: To assess the cost-effectiveness of tapentadol prolonged release
compared to morphine, oxycodone, hydromorphone, transdermal buprenorphine
[TDB], and transdermal fentanyl [TDF] for the treatment of severe chronic non-
cancer pain in Belgium. METHODS: A one year Markov transition state model with
4-week cycles was built. Four health states were defined: ‘no withdrawal and no
adverse events treated’, ’occurrence of adverse events (AEs) with need for medical
treatment’, ’withdrawal due to AEs’, and ‘withdrawal due to lack of efficacy’. Pa-
tients who were lacking efficacy or had poor tolerability switched to an alternative
2nd line opioid (oxycodone, morphine, hydromorphone, TDB or TDF). 3rd line ther-
apy was the absorbing state. Data regarding efficacy, tolerability and utility values
(EQ-5D) were derived from clinical trials and published literature. Switch rates to
2nd line therapies and resource consumption were estimated by clinical experts.
Costs were calculated from the health care payer perspective including patients’
co-payments as stated in the Belgium pharmacoeconomic guidelines. One-way,
scenario, and probabilistic sensitivity analyses were conducted. RESULTS: Com-
pared to oxycodone (direct comparison data), tapentadol had almost the same cost
but higher effectiveness, resulting in the incremental cost-effectiveness ratio
(ICER) of 6 EUR per QALY gained. The ICERs of tapentadol versus TDB, TDF, hydro-
morphone and morphine equaled to 2,407, 5,811, 19,852, and 23,182 EUR per QALY
gained, respectively. In the univariate sensitivity analysis, resource consumption,
probabilities and utilities were varied for 50%, 20% and 10%, respectively.
Conclusions about the cost-effectiveness of tapentadol remained robust, especially
when compared to oxycodone, TDF and TDB, which account for ca. 90% of the total
strong opioid market in Belgium. The ICER in these cases did not exceed 10,000 EUR
per QALY gained. CONCLUSIONS: To improve pain relief and quality of life in
patients with severe chronic pain tapentadol appears to be the favourable and
cost-effective treatment option in Belgium.
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OBJECTIVES: Currently, anti-TNF monoclonal antibodies are the mainstay of
therapy in patients with active rheumatoid arthritis (RA) and inadequate response
to methotrexate (MTX) alone. The purpose of this analysis is to evaluate the cost-
effectiveness of certolizumab pegol (CZP) versus other anti-TNF (adalimum-
ab[ADA], infliximab [INF] and etanercept [ETA]) as adjunctive therapy to MTX from
the perspective of the Brazilian private health care system. METHODS: Cost-effec-
tiveness for 52 weeks of treatment was evaluated based on the ACR20 response rate
at week 24 based on main published RCTs for each anti- TNF. An indirect compar-
ison was performed using Glenny et al method1. Annual drug costs for each aTNF
were calculated from their published ex-factory prices and their recommended
dosing schedule in the Brazilian product information. For the calculation of the
annual INF cost, the initial weight of the patient assumed for the model was as-
sumed to be 65Kg, with no increment of the doses after 22 weeks. Results are
presented in USD (June 11th, 2012 exchange rate) annual costs and incremental
cost-effectiveness ratios (ICER’s). A sensitivity analysis was made on price discount
rate. RESULTS: Annual costs were estimated in USD $12,619, USD $39,305, USD
$24,267 and USD $35,617 for CZP, ADA, INF and ETA, respectively. Adjusted by
indirect comparison of ACR20 response were 77% for CZP and 67%, 61% and 45%
for ADA, INF and ETA, respectively. The cost effective ratio was USD $16,484 for
CZP and USD $79,742, USD $59,326, USD $40,299 for ETA, ADA and INF respec-
tively. The cost-effectiveness analysis demonstrated that CZP was a dominant
strategy compared with ADA, INF and ETA. CONCLUSIONS: Certolizumab pegol
(CZP) is a cost- saving anti-TNF option for treating RA from a Brazilian private
health care perspective.
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OBJECTIVES: Cost-effectiveness of denosumab versus other treatments in MOP in
 75-year-olds in Sweden was evaluated from a third-party payer perspective.
METHODS: A lifetime cohort Markov model was developed with seven health
states: well, hip fracture, vertebral fracture, other osteoporotic fracture, post hip
fracture, post vertebral fracture, and dead. During each cycle, patients could have
a fracture, remain healthy, remain in a post fracture state or die. Background frac-
ture risks, mortality rates, persistence rates, utilities, medical and drug costs were
derived using published sources. BMD improvements have been shown to be sim-
ilar across MOP and post-menopausal osteoporotic (PMO) populations; therefore in
the absence of well-powered trials evaluating fracture risk reduction in MOP, effi-
cacy was obtained from studies in PMO women. Lifetime expected costs and qual-
ity-adjusted life-years (QALYs) were estimated for denosumab, generic alendro-
nate, generic risedronate, ibandronate, zoledronate, strontium ranelate and
teriparatide. On average, patients in the model were 78 year-old men, with bone
mineral density T-score-2.12 and prevalent vertebral fracture of 23%. In the base-
case, the model assumed patients could receive treatment effects up to 5 years
after discontinuation, except on teriparatide (only 2 years). Costs and QALYs were
discounted at 3% annually. Extensive sensitivity analyses were conducted.
RESULTS: Total lifetime costs for denosumab, alendronate, zoledronate, strontium
ranelate, risedronate, ibandronate and teriparatide were €31,324, €34,834, €35,592,
€35,939, €36,008, €37,211 and €38,632, respectively. Total QALYs were 5.22, 5.12,
5.15, 5.12, 5.11, 5.09 and 5.19, respectively. Denosumab dominated all treatments by
having lower costs and higher QALYs. Denosumab dominated generic alendronate
(next least expensive strategy) in the one-way sensitivity analyses also. The prob-
ability of denosumab being cost-effective compared to the other treatments at a
threshold of €66,000/QALY was 99.0%. CONCLUSIONS: Denosumab dominated al-
most all comparators, including generic bisphosphonates in the Swedish MOP pop-
ulation  75 years-old.
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OBJECTIVES: To assess the cost-effectiveness of denosumab and zoledronate in
preventing fractures related to osteoporosis in postmenopausal women from the
private health care sector perspective in Brazil. METHODS: A previously validated
Markov model comprising eight health states (no fracture, hip, vertebral, wrist and
other osteoporotic fractures, post hip and post vertebral fractures, and death)
quantified lifetime costs and benefits within six-month intervals. Analyzed popu-
lation consisted of postmenopausal women 72 years. Age-related risk fracture
was modeled and fracture-specific risk reductions of each targeted therapy were
computed. Efficacy data were derived from published randomized clinical trials.
The analysis included direct costs using ex-factory drug prices. Medical and labo-
ratory costs came from the Brazilian Medical Association reimbursement list. Frac-
ture-related (i.e., hospitalization, surgery) and follow-up (i.e., rehabilitation) costs
were extracted from a private health care database (BI2im). Costs were reported in
2012 Brazilian currency (1BRL0.52USD). Outcomes assessed were 10-year fracture
event incidence and quality-adjusted life years (QALYs). Costs and benefits were
discounted 5% yearly. Univariate and multivariate (probabilistic) sensitivity anal-
yses tested model robustness. RESULTS: Average morbidity costs were BRL2,722
and BRL2,839 for denosumab and zoledronate, respectively. Intervention costs
were BRL5,153 for denosumab and BRL5,481 for zoledronate. Lifetime cost differ-
ence between alternatives was BRL446 per patient treated. Ten-year fracture inci-
dence was lower with denosumab: reductions of 0.5% and 1.5% for hip and verte-
bral fractures, respectively, over zoledronate. Average QALYs were 6.861 and 6.841
for denosumab and zoledronate. Denosumab reduced fracture incidence and im-
proved QALYs at a lower cost. Denosumab remained cost-efffective after changes
in individual model parameters (up to 20% variability), considering a willingness-
to-pay of BRL57,000/QALY gained (3x Brazilian GDP/capita). Multivariate sensitivity
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